tradingkey.logo

Nuwellis Q4 revenue rises on US console growth

ReutersMar 10, 2026 12:23 PM


Overview

  • Medical technology firm's Q4 revenue grew 4% yr/yr, driven by U.S. console sales

  • Gross margin improved to 68.2% from 58.4% in prior-year quarter

  • Company announced $5 mln private placement and Rendiatech acquisition


Outlook

  • Nuwellis aims to integrate Rendiatech acquisition and expand cardiorenal portfolio in 2026

  • Company plans to progress development of Vivian, a pediatric solution, in 2026

  • Nuwellis focuses on driving consistent commercial execution and deeper utilization in 2026


Result Drivers

  • CONSOLE SALES - 208% increase in U.S. console sales drove Q4 revenue growth

  • GROSS MARGIN IMPROVEMENT - Gross margin rose to 68.2% due to improved pricing and product mix

  • HEART FAILURE AND PEDIATRICS - Heart Failure revenue increased 48% and Pediatrics increased 16% in Q4


Company press release: ID:nGNX77jFp2


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Beat

$2.42 mln

$2.31 mln (1 Analyst)

Q4 EPS

-$1.50

Q4 Net Income

-$2.42 mln

Q4 Gross Profit

$1.65 mln

Q4 Income from Operations

-$2.44 mln

Q4 Pretax Profit

-$2.42 mln


Analyst Coverage

  • The one available analyst rating on the shares is "hold"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
KeyAI